Substrate
Topic

head-and-neck-cancer

1 stories related to this topic, newest first.

Amivantamab Shows Tumor Responses in 43 of 102 Patients with Advanced Head and Neck CancerThe Guardian
health1 day ago

Amivantamab Shows Tumor Responses in 43 of 102 Patients with Advanced Head and Neck Cancer

An international trial found the Johnson & Johnson drug shrank or eliminated tumors in 43 of 102 patients whose disease had resisted prior chemotherapy and immunotherapy. Results will be presented Sunday at the American Society of Clinical Oncology meeting in Chicago.

The Guardian
1 source